$4.26
4.48% today
Nasdaq, Apr 04, 08:16 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$4.46
-1.53 25.54% 1M
-1.69 27.48% 6M
-2.75 38.14% YTD
-4.83 51.99% 1Y
-1.87 29.54% 3Y
+1.56 53.79% 5Y
-232.84 98.12% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.32 6.69%
ISIN
US02155H1014
Symbol
ALT
Sector
Industry

Key metrics

Market capitalization $343.48m
Enterprise Value $213.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10,661.50
P/S ratio (TTM) P/S ratio 17,174.00
P/B ratio (TTM) P/B ratio 2.61
Revenue growth (TTM) Revenue growth -95.31%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-103.17m
Free Cash Flow (TTM) Free Cash Flow $-79.85m
Cash position $131.93m
EPS (TTM) EPS $-1.34
P/E forward negative
P/S forward 120,224.01
EV/Sales forward 74,634.23
Short interest 29.39%
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Altimmune, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.02 0.02
95% 95%
100%
- Direct Costs 0.24 0.24
-
1,200%
-0.22 -0.22
-
-1,100%
- Selling and Administrative Expenses 20 20
23% 23%
102,450%
- Research and Development Expense 82 82
25% 25%
411,150%
-103 -103
24% 24%
-514,650%
- Depreciation and Amortization 0.24 0.24
-
1,200%
EBIT (Operating Income) EBIT -103 -103
24% 24%
-515,860%
Net Profit -95 -95
7% 7%
-475,300%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Positive
The Motley Fool
13 days ago
Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.
Positive
Seeking Alpha
18 days ago
Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start i...
Positive
Reuters
22 days ago
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website www.altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today